Patents by Inventor Yoshirou KAWAGUCHI

Yoshirou KAWAGUCHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-ALK2 antibody
    Patent number: 11447554
    Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: September 20, 2022
    Assignees: Saitama Medical University, Daiichi Sankyo Company, Limited
    Inventors: Takenobu Katagiri, Kenji Osawa, Sho Tsukamoto, Shinnosuke Tsuji, Yoshirou Kawaguchi, Kensuke Nakamura
  • Anti-ALK2 antibody
    Patent number: 11312776
    Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: April 26, 2022
    Assignees: Saitama Medical University, Daiichi Sankyo Company, Limited
    Inventors: Takenobu Katagiri, Kenji Osawa, Sho Tsukamoto, Shinnosuke Tsuji, Yoshirou Kawaguchi, Kensuke Nakamura
  • ANTI-ALK2 ANTIBODY
    Publication number: 20220041738
    Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
    Type: Application
    Filed: October 26, 2021
    Publication date: February 10, 2022
    Applicants: Saitama Medical University, Daiichi Sankyo Company, Limited
    Inventors: Takenobu KATAGIRI, Kenji OSAWA, Sho TSUKAMOTO, Shinnosuke TSUJI, Yoshirou KAWAGUCHI, Kensuke NAKAMURA
  • Endos mutant enzyme
    Patent number: 11001819
    Abstract: The present invention provides an EndoS mutant enzyme having an amino acid sequence of EndoS D233Q and further having a particular additional mutation and exhibiting a reduced hydrolysis activity, in comparison with the activity of EndoS D233Q, to an N-linked sugar chain (N297-linked sugar chain) linked to Asn at position 297 in IgG and a gene encoding the same.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: May 11, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yoshirou Kawaguchi, Kensuke Nakamura, Yukiko Sekiguchi, Mitsuhiro Iwamoto
  • ANTI-ALK2 ANTIBODY
    Publication number: 20200002427
    Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
    Type: Application
    Filed: August 19, 2019
    Publication date: January 2, 2020
    Applicants: SAITAMA MEDICAL UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: TAKENOBU KATAGIRI, KENJI OSAWA, SHO TSUKAMOTO, SHINNOSUKE TSUJI, YOSHIROU KAWAGUCHI, KENSUKE NAKAMURA
  • Anti-ALK2 antibody
    Patent number: 10428148
    Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: October 1, 2019
    Assignees: Saitama Medical University, Daiichi Sankyo Company, limited
    Inventors: Takenobu Katagiri, Kenji Osawa, Sho Tsukamoto, Shinnosuke Tsuji, Yoshirou Kawaguchi, Kensuke Nakamura
  • NOVEL ENDOS MUTANT ENZYME
    Publication number: 20180208915
    Abstract: The present invention provides an EndoS mutant enzyme having an amino acid sequence of EndoS D233Q and further having a particular additional mutation and exhibiting a reduced hydrolysis activity, in comparison with the activity of EndoS D233Q, to an N-linked sugar chain (N297-linked sugar chain) linked to Asn at position 297 in IgG and a gene encoding the same.
    Type: Application
    Filed: July 15, 2016
    Publication date: July 26, 2018
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yoshirou Kawaguchi, Kensuke Nakamura, Yukiko Sekiguchi, Mitsuhiro Iwamoto
  • ANTI-ALK2 ANTIBODY
    Publication number: 20180118835
    Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
    Type: Application
    Filed: January 29, 2016
    Publication date: May 3, 2018
    Applicants: Saitama Medical University, Daiichi Sankyo Company, Limited
    Inventors: Takenobu Katagiri, Kenji OSAWA, Sho TSUKAMOTO, Shinnosuke TSUJI, Yoshirou KAWAGUCHI, Kensuke NAKAMURA